Artal Group S.A. acquired a new position in shares of Synlogic Inc (NASDAQ:SYBX) in the fourth quarter, HoldingsChannel reports. The firm acquired 550,000 shares of the biotechnology company’s stock, valued at approximately $5,335,000.
Synlogic Inc (NASDAQ SYBX) opened at $10.98 on Friday. Synlogic Inc has a one year low of $8.76 and a one year high of $23.00. The company has a market cap of $231.91, a PE ratio of -1.16 and a beta of 2.91.
A number of equities analysts have recently commented on SYBX shares. Zacks Investment Research downgraded shares of Synlogic from a “hold” rating to a “sell” rating in a research note on Wednesday, November 22nd. ValuEngine downgraded shares of Synlogic from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Wedbush started coverage on shares of Synlogic in a research note on Monday, November 27th. They set an “outperform” rating and a $20.00 price objective for the company. Finally, Piper Jaffray Companies started coverage on shares of Synlogic in a research note on Monday, January 29th. They set an “overweight” rating and a $16.00 price objective for the company. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. Synlogic presently has an average rating of “Hold” and a consensus target price of $18.75.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://ledgergazette.com/2018/02/18/artal-group-s-a-takes-5-34-million-position-in-synlogic-inc-sybx.html.
Synlogic Company Profile
Synlogic, Inc, formerly Mirna Therapeutics, Inc, is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU).
Want to see what other hedge funds are holding SYBX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Synlogic Inc (NASDAQ:SYBX).
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.